Patent Director Turns Away Pair of Amgen Challenges to Opdivo IP – Bloomberg Law News

Challenges to two patents covering dosing options for Bristol-Myers Squibb Co.’s blockbuster Opdivo cancer drug were turned away by the US Patent …